Literature DB >> 7020917

A randomized comparative trial of chemotherapy and irradiation therapy for stage II breast cancer.

M R Cooper, A L Rhyne, H B Muss, C Ferree, F Richards, D R White, J J Stuart, D V Jackson, V Howard, A Shore, C L Spurr.   

Abstract

One hundred fifty-eight evaluable patients with Stage II carcinoma of the breast with positive lymph nodes were treated either with adjuvant chemotherapy or irradiation therapy followed by chemotherapy. Patients were randomized to test the effectiveness of L-phenylalanine mustard (L-PAM) with and without postoperative irradiation therapy (R.T.) against cyclophosphamide, 5-fluorouracil, and methotrexate (CMF) with and without postoperative irradiation therapy in decreasing the frequency of recurrence. No significant difference was observed between L-PAM as compared with R.T. plus L-PAM (P = 0.85). The difference between CMF and R.T. plus CMF was significant in support of CMF alone (P = 0.04). The frequency of recurrence between R.T. plus L-PAM and R.T. plus CMF showed no difference. A comparison of the chemotherapy only regimens showed an advantage of CMF over L-PAM (P = 0.05). Both the delay in starting chemotherapy and the significant decrease in percent optimal drug dosage during the first six cycles of therapy are factors that may influence the high frequency of relapse observed in the R.T. plus chemotherapy groups. Of the four treatments, CMF has the lowest frequency of recurrence.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7020917     DOI: 10.1002/1097-0142(19810615)47:12<2833::aid-cncr2820471214>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

Review 1.  The role of post-operative radiotherapy in the treatment of operable breast cancer.

Authors:  G F Beadle; J R Harris
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872

2.  Adjuvant use of cytotoxic chemotherapy to destroy micrometastasis in breast cancer after local control therapy--current status.

Authors:  S K Carter
Journal:  Clin Exp Metastasis       Date:  1983 Jan-Mar       Impact factor: 5.150

3.  Influence of radiotherapy on the dose of adjuvant chemotherapy in early breast cancer.

Authors:  F Habibollahi; I S Fentiman; M A Chaudary; P J Winter; D Tong; J L Hayward; Z Doran; R D Rubens
Journal:  Breast Cancer Res Treat       Date:  1989-07       Impact factor: 4.872

4.  Adjuvant chemotherapy of breast cancer: hope--reality--hazard?

Authors:  H Vorherr
Journal:  Klin Wochenschr       Date:  1984-02-15

5.  Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy.

Authors:  Pauline T Truong; Ivo A Olivotto; Timothy J Whelan; Mark Levine
Journal:  CMAJ       Date:  2004-04-13       Impact factor: 8.262

Review 6.  Comparative activity of ifosfamide and cyclophosphamide.

Authors:  W Brade; S Seeber; K Herdrich
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  A randomized trial of chemotherapy (L-PAM vs CMF) and irradiation for node positive breast cancer. Eleven year follow-up of a Piedmont Oncology Association trial.

Authors:  H B Muss; M R Cooper; J K Brockschmidt; C Ferree; F Richards; D R White; D V Jackson; C L Spurr
Journal:  Breast Cancer Res Treat       Date:  1991-10       Impact factor: 4.872

Review 8.  Adjuvant chemotherapy of cancer. A review of its current status.

Authors:  S K Carter
Journal:  Drugs       Date:  1986-04       Impact factor: 9.546

9.  Feasibility of a dose-intensive CMF regimen with granulocyte colony-stimulating factor as adjuvant therapy in premenopausal patients with node-positive breast cancer.

Authors:  A M Bos; H de Graaf; E G de Vries; H Piersma; P H Willemse
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

Review 10.  Postmastectomy radiation therapy: an overview for the practicing surgeon.

Authors:  Reshma Jagsi
Journal:  ISRN Surg       Date:  2013-09-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.